Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3

Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 5

Abstract

Introduction. Progressive familial intrahepatic cholestasis type 3 (PFIC-3) is a severe liver disorder associated with inherited dysfunction of multidrug resistance protein 3 (MDR3/ABCB4), which functions as a phospholipid floppase, translocating phosphatidylcholine from the inner to the outer hemileaflet of the canalicular membrane of hepatocytes. MDR3 deficiency results in a disbalanced bile which may damage the luminal membrane of cells of the hepatobiliary system. We evaluated clinical, biochemical and histological improvement in a genetically proven PFIC-3 patient after long-term ursodeoxycholic acid (UDCA) administration. Material and methods. A PFIC-3 patient and a relative with cholestatic liver disease were studied. Hepatic MDR3 expression was analyzed by immunohistochemistry and ABCB4 mutations were identified. The effect of the mutations on MDR3 expression and subcellular localization was studied in vitro. Results. A 23-year-old man presented cholestasis with severe fibrosis and incomplete cirrhosis. Canalicular staining for MDR3 was faint. Sequence analysis of ABCB4 revealed two missense mutations that reduce drastically protein expression levels. After 9 years of treatment with UDCA disappearance of fibrosis and cirrhosis was achieved. Conclusion. These data indicate that fibrosis associated with MDR3 deficiency can be reversed by long-term treatment with UDCA, at least when there is residual expression of the protein.

Authors and Affiliations

Bernardo Frider, Amalia Castillo, Raquel Gordo-Gilart, Andrés Bruno, Marcelo Amante, Luis Alvarez, Verónica Mathet

Keywords

Related Articles

Current indications for the use of albumin in the treatment of cirrhosis

The role of proteins in the maintenance of colloid osmotic pressure has been described by Starling since 1896. For many decades, the importance of albumin was associated exclusively to its colloid osmotic function. More...

Mexican-native human echinococcosis: Case report of an underestimated disease

Mexico is considered a virtually free region of cystic echinococcosis. Almost all case reports within the country involve immigrants or traveling patients. This manuscript presents a Mexican-native human echinococcosis t...

Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis

Fibrosing cholestatic hepatitis (FCH) is an aggressive and usually fatal form of viral hepatitis in immunocompromised patients. It is characterized by progressive cholestasis leading to hepatic failure, and a characteris...

Hepatitis B viral load and risk of HBV-related liver disease: from East to West?

Chronic hepatitis B has a variable course in disease activity with a risk of clinical complications like liver cirrhosis and hepatocellular carcinoma. As clinical symptoms present in a late stage of the disease, identifi...

Download PDF file
  • EP ID EP78502
  • DOI -
  • Views 121
  • Downloads 0

How To Cite

Bernardo Frider, Amalia Castillo, Raquel Gordo-Gilart, Andrés Bruno, Marcelo Amante, Luis Alvarez, Verónica Mathet (2015). Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3. Annals of Hepatology, 14(5), 745-751. https://europub.co.uk/articles/-A-78502